Ftse Mib
34.374,77
0,55%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.735,92
-0,17%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vivos Therapeutics Inc (VVOS) Vivos Therapeutics Inc (VVOS) Notizie

VVOS

Vivos Therapeutics (VVOS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VVOS
DataOraFonteTitoloSimboloCompagnia
26/12/202413:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VVOSVivos Therapeutics Inc
23/12/202423:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
23/12/202414:00GlobeNewswire Inc.Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:VVOSVivos Therapeutics Inc
20/12/202421:17Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VVOSVivos Therapeutics Inc
27/11/202422:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VVOSVivos Therapeutics Inc
14/11/202422:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
14/11/202422:05GlobeNewswire Inc.Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
13/11/202423:00GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
06/11/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VVOSVivos Therapeutics Inc
08/10/202413:30GlobeNewswire Inc.Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical AssociationNASDAQ:VVOSVivos Therapeutics Inc
24/09/202420:59Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VVOSVivos Therapeutics Inc
19/09/202413:00GlobeNewswire Inc.Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesNASDAQ:VVOSVivos Therapeutics Inc
18/09/202423:15AllPennyStocks.comHealthcare Shares Pop On FDA ClearanceNASDAQ:VVOSVivos Therapeutics Inc
18/09/202413:00GlobeNewswire Inc.Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and SnoringNASDAQ:VVOSVivos Therapeutics Inc
14/08/202422:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VVOSVivos Therapeutics Inc
14/08/202422:05GlobeNewswire Inc.Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
14/08/202413:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
08/08/202423:19Edgar (US Regulatory)Form 424B1 - Prospectus [Rule 424(b)(1)]NASDAQ:VVOSVivos Therapeutics Inc
08/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VVOSVivos Therapeutics Inc
30/07/202412:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VVOSVivos Therapeutics Inc
27/06/202413:30GlobeNewswire Inc.Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution ModelNASDAQ:VVOSVivos Therapeutics Inc
12/06/202413:30GlobeNewswire Inc.Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution AllianceNASDAQ:VVOSVivos Therapeutics Inc
20/05/202419:04GlobeNewswire Inc.Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified DirectorsNASDAQ:VVOSVivos Therapeutics Inc
14/05/202422:05GlobeNewswire Inc.Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
14/05/202413:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
09/04/202413:30GlobeNewswire Inc.Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementNASDAQ:VVOSVivos Therapeutics Inc
28/03/202421:05GlobeNewswire Inc.Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
28/03/202412:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
15/02/202414:00GlobeNewswire Inc.Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsNASDAQ:VVOSVivos Therapeutics Inc
14/02/202423:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VVOS

La tua Cronologia

NASDAQ
SASI
Sigma Additive Solutions
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network